ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Limited has fixed September 12, 2026, as the record date to determine shareholder eligibility for the dividend for FY 2025-26.
Bharat Parenterals Limited has submitted its Annual Report for the financial year 2025-26. The report includes the notice for the 33rd Annual General Meeting.
Bharat Parenterals Limited has scheduled its 33rd Annual General Meeting on September 19, 2026, to discuss financial results, dividend declaration, and director reappointments.
Bharat Parenterals Limited shares have been admitted to trade on the National Stock Exchange under the 'Permitted to Trade' category effective August 17, 2026.
Bharat Parenterals is upgrading its subsidiary Varenyam Biolifesciences' Savli facility for biologics and biosimilars. This expansion involves a revised Phase 1 capital expenditure of ₹300 Crore.
Q1 FY27 consolidated revenue fell 19% YoY to ₹93.7 Cr due to standalone institutional order base effects. Gross margins expanded 1,000bps to 50.6%, though consolidated PAT remained negative at ₹(3.6) Cr.
Bharat Parenterals Ltd re-appointed Mr. Hemang Shah as Executive Director for a five-year term. The appointment is subject to shareholder approval at the ensuing AGM.
Bharat Parenterals Ltd reported revenue from operations of ₹93.7 Cr (-19.2% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
Bharat Parenterals Limited has scheduled a board meeting for August 05, 2026. The board will consider and approve unaudited financial results for the quarter ended June 2026.
Promoter Desai Shares and Stock Private Limited acquired 1,356 equity shares on market. Holding increased from 39.65% to 39.67%.
Promoter entity Desai Shares and Stock Private Ltd purchased 900 BSE-listed shares for Rs.0.13 Crore. This increases promoter holding from 39.63% to 39.65%.
Desai Shares & Stock Pvt Ltd, a promoter, bought 900 shares (0.013%) of Bharat Parenterals Ltd in the open market (June 3‑15 2026). The stake rise signals confidence.
Bharat Parenterals submitted its FY2026 Annual Secretarial Compliance Report. The independent auditor confirmed compliance with SEBI regulations, noting only a minor past administrative fine.
Bharat Parenterals reported flat FY26 consolidated revenue of ₹345.4cr but a 6x EBITDA surge to ₹15.8cr. Transition year focused on regulatory clearances and scaling subsidiaries like Innoxel and Varenyam.
Bharat Parenterals calls FY26 a 'bridge year' of transition, clearing regulatory hurdles and scaling subsidiaries despite flat consolidated revenue of ₹345.4 cr. Growth in high-margin subsidiaries Inoxxel and Verineum offset a 23% decline in standalone exports.
Bharat Parenterals FY26 results show a transition phase with consolidated revenue of ₹345.4Cr and a PAT loss of ₹27.3Cr, driven by heavy R&D and subsidiary investment.
Bharat Parenterals re-appointed its Cost and Internal Auditors for the 2026-27 financial year. Both firms possess over 16 years of experience, ensuring continued regulatory compliance.
Bharat Parenterals Ltd reported revenue from operations of ₹99.6 Cr (-4.2% YoY) and a net loss of ₹8.2 Cr for Q4 FY26.
Bharat Parenterals reported FY26 consolidated revenue of ₹345.4 Crore and recommended a ₹0.07 Crore dividend. The board also re-appointed cost and internal auditors.
Bharat Parenterals Limited scheduled a board meeting for May 18, 2026. Directors will consider FY2026 audited financial results and recommend a final equity dividend.
Bharat Parenterals Limited (BSE: 541096) confirmed it does not fall under the 'Large Corporate' category as of March 31, 2026. The company reported outstanding borrowings of ₹15.77 Crore, which is below the threshold for mandatory debt-market borrowing requirements under SEBI circulars.
Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, concluded a U.S. FDA inspection at its Vadodara facility with five procedural observations under a Voluntary Action Indicated (VAI) classification. The inspection occurred in April 2026. The company maintains its commitment to quality standards and will submit responses within prescribed timelines.
Bharat Parenterals Ltd clarified to the BSE that recent stock price movements are market-driven. The company confirmed it has no undisclosed material information or impending announcements that could impact price or volume behavior and remains in compliance with SEBI Listing Regulations.
Bharat Parenterals Ltd reported a net loss of ₹9.7 Cr for Q3 FY26.
Bharat Parenterals Limited submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent, Adroit Corporate Services, confirmed that securities received for dematerialisation were processed and listed on stock exchanges within the mandated 15-day period.